small molecule

TURALIO

PEXIDARTINIB HYDROCHLORIDE

Loss of exclusivityJuly 2038latest FDA-listed patent expiry

CompanyDaiichi Sankyo →See this company's full patent-cliff portfolio

Drug detail

Brand name	TURALIO
Active ingredient	PEXIDARTINIB HYDROCHLORIDE
Strength	EQ 125MG BASE
Dosage form	CAPSULE
Route	ORAL
Modality	Small molecule
FDA approval	October 2022
Marketing status	RX

Listed patents

Patent	Expires	Type
10961240	July 2038	use U-2606
10941142	July 2038	product
10435404	July 2038	product
10730876	May 2036	substance
10189833	May 2036	use U-2606
9802932	May 2036	substance
9358235	June 2033	use U-2606
7893075	May 2033	substance
8461169	April 2028	use U-2606
8404700	November 2027	substance
8722702	November 2027	substance
9169250	November 2027	substance

Regulatory exclusivity

Code	Expires
ODE*	August 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Daiichi Sankyo